Conduit Pharmaceuticals (CDT) announces the successful completion of all milestones in Phase I of its strategic collaboration with Sarborg Limited. This transition to Phase II marks a positive step forward in Conduit’s strategy to explore the integration advanced artificial intelligence and cybernetics into its drug development processes. With Phase I now complete, the Company transitions to Phase II, which will focus on the creation of personalized software dashboards to enhance operational efficiency and reporting.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals files to sell 5.9M shares of common stock for holders
- Upcoming Stock Splits This Week (January 27 to January 31) – Stay Invested
- Conduit Pharmaceuticals Inc trading halted, news pending
- Conduit Pharmaceuticals Implements Reverse Stock Split Plan
- Conduit Pharmaceuticals board approves 1-for-100 reverse stock split